Immune Checkpoint Inhibitor Clinical Trials

42 recruitingLast updated: June 18, 2026

There are 42 actively recruiting immune checkpoint inhibitor clinical trials across 11 countries. Studies span Phase 2, Not Applicable, Phase 3, Phase 1. Top locations include Beijing, Beijing Municipality, China, Paris, France, Beijing, China. Updated daily from ClinicalTrials.gov.


Immune Checkpoint Inhibitor Trials at a Glance

42 actively recruiting trials for immune checkpoint inhibitor are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in Beijing, Paris, and Beijing. Lead sponsors running immune checkpoint inhibitor studies include Second Xiangya Hospital of Central South University, Sun Yat-sen University, and Groupe Hospitalier Pitie-Salpetriere.

Browse immune checkpoint inhibitor trials by phase

Treatments under study

About Immune Checkpoint Inhibitor Clinical Trials

Looking for clinical trials for Immune Checkpoint Inhibitor? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune Checkpoint Inhibitor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune Checkpoint Inhibitor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 42 trials

Recruiting
Phase 3

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting

AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis

Immune Checkpoint Inhibitor-Related MyocarditisArrhythmiaLong QT Syndrome
Groupe Hospitalier Pitie-Salpetriere127,000 enrolled1 locationNCT07644715
Recruiting

ATROPOS: Survival Analysis of ICI-associated Myocarditis

Immune Checkpoint Inhibitor-associated Myocarditis
Groupe Hospitalier Pitie-Salpetriere1,500 enrolled1 locationNCT07633587
Recruiting
Phase 2

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

MelanomaImmune Checkpoint InhibitorImmune-related Adverse Event
Sun Yat-sen University55 enrolled2 locationsNCT07644897
Recruiting

Global Cardio Oncology Registry

Breast CancerCardiotoxicityCardiovascular Diseases+2 more
The Cleveland Clinic5,000 enrolled1 locationNCT05598879
Recruiting
Phase 3

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

ChemotherapyRadiotherapyImmune Checkpoint Inhibitor+1 more
Sun Yat-sen University380 enrolled3 locationsNCT05941741
Recruiting
Phase 2

Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors

Lung CancerRadiotherapyImmune Checkpoint Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital30 enrolled3 locationsNCT07058948
Recruiting

Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Lung CancerVenous ThromboembolismArterial Thromboembolism+1 more
Beijing Chao Yang Hospital2,400 enrolled5 locationsNCT06950697
Recruiting
Phase 2

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

Stomach NeoplasmsImmune Checkpoint Inhibitors
Xijing Hospital116 enrolled5 locationsNCT06576921
Recruiting

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Immune Checkpoint InhibitorsArthritisPolymyalgia Rheumatica
M.D. Anderson Cancer Center20 enrolled1 locationNCT06647134
Recruiting
Not Applicable

Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations and Immune Infiltrate Characterization : the UTOPIC Project

Inflammatory ArthritisRare Auto-immune DiseasesImmune Checkpoint Inhibitor Related Inflamamtory Arthritis
University Hospital, Brest100 enrolled2 locationsNCT07302074
Recruiting

Observational Cohort Study of Chronic Viral Infection in the Central Nervous System

Immune Checkpoint InhibitorsProgressive Multifocal Leukoencephalopathy
Peking Union Medical College Hospital66 enrolled1 locationNCT07512518
Recruiting
Phase 2

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Non-small Cell Lung CancerImmune Checkpoint Inhibitors (ICIs)
Second Xiangya Hospital of Central South University70 enrolled20 locationsNCT06951646
Recruiting

Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.

Breast CancerLiver CancerColorectal, Cancer+4 more
Gene Solutions50 enrolled2 locationsNCT06227728
Recruiting
Phase 2

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

Immune Checkpoint Inhibitor-Related Colitis
Shilpa Grover, MD, MPH80 enrolled2 locationsNCT06841705
Recruiting
Phase 2

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial

Immune Checkpoint Inhibitors (ICI)-Related Dermatitis
Shixiu Wu35 enrolled1 locationNCT06715982
Recruiting

FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis

Hematologic MalignancyMyocarditisSubclinical Immune Checkpoint Inhibitor-Induced Myocarditis+4 more
Mayo Clinic30 enrolled1 locationNCT06566209
Recruiting
Phase 3

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

Radiotherapy, AdjuvantHepatocellular Carcinoma (HCC)Immune Checkpoint Inhibitor+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences286 enrolled1 locationNCT07186621
Recruiting
Phase 2

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Renal Cell CarcinomaRadiotherapyImmune Checkpoint Inhibitor
Jinling Hospital, China35 enrolled1 locationNCT06255223
Recruiting

The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study

Unresectable Hepatocellular CarcinomaPsychological DistressHCC - Hepatocellular Carcinoma+2 more
Guilin Medical University, China700 enrolled5 locationsNCT07141056